Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADV placebo Clear all
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

NCT00695877
View directory record Official record
Conditions
HIV Infections
Interventions
Ad5.ENVA.48 HIV-1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 10:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

NCT01006798
View directory record Official record
Conditions
Bird Flu, Influenza
Interventions
Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
Other · Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 40 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
4
States / cities
Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309
View directory record Official record
Conditions
Norovirus Infection
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 2, 2026, 10:19 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

NCT06620003
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Not listed Phase 3 Interventional

Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization

NCT00438867
View directory record Official record
Conditions
Angina Pectoris
Interventions
Ad5FGF-4, Placebo
Genetic
Lead sponsor
Cardium Therapeutics
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 2, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230
View directory record Official record
Conditions
Coronavirus Infection
Interventions
NasoVAX, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

NCT03964415
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
3,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield Study of Safety and Immunogenicity

NCT03352466
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, BioThrax, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Melbourne, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 2, 2026, 10:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 10:19 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

NCT02366013
View directory record Official record
Conditions
HIV
Interventions
rcAd26.MOS1.HIV-Env 1x10^8 vp, rcAd26.MOS1.HIV-Env 1x10^9 vp, rcAd26.MOS1.HIV-Env 1x10^10 vp, rcAd26.MOS1.HIV-Env 1x10^11 vp
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 2, 2026, 10:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Challenge Study

NCT05212168
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 2, 2026, 10:19 PM EDT